Pharma Mar is a biopharmaceutical company focused on the research, development, production, and commercialization of bioactive products of marine origin for oncology. Founded in 1986, the company explores marine invertebrates to identify antitumor compounds, managing the entire process from discovery to formulation. Its business segments include the development of marine-derived anticancer drugs and the management of subsidiaries dedicated to the commercialization of these products in Europe and the development of RNA interference. The company serves patients with cancer and other serious diseases, with its approved medications reaching international markets through a network of partners. Pharma Mar maintains a subsidiary in Germany and operates internationally, leveraging a collection of marine invertebrate samples to drive its therapeutic platform.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Biotechnology Homepage pharmamar.com
Sector Healthcare IR page pharmamar.com/es
Tags
marine biotechnology, oncology, antitumor drugs, rna interference, marine invertebrates, biopharmaceuticals
Press page —

Metrics

Valuation  
Market cap € 1.16B
Market cap (USD) $ 1.282B
P/E 20.66
PEG 1.38
P/BV 4.63
P/S 5.31
P/OCF 18.65
P/FCF 24.86
Dividend yield —
Turnover / mcap —
Returns  
ROE 32.6%
ROI 26.1%
ROIC 21.1%
Profit margin 33.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 15.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) —
Debt/Equity 14.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 91
Quality score 25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 221.39M 174.855M 158.153M 196.343M 229.831M 269.961M 85.819M 162.588M 179.363M 180.947M 193.817M 149.652M 141.824M 138.229M 152.486M 153.508M
Net profit 74.986M 26.125M 1.137M 49.356M 92.859M 137.262M -11.397M -5.552M -26.763M -24.108M 6.563M 13.095M 11.133M 3.725M -1.373M -12.332M
Free cash flow 46.668M -8.988M -29.402M 29.469M 17.874M 275.94M -28.12M — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 72.3 78.65 32.6 46.97 53.23 73.46 — — — — — — — — — —
Price performance 12m -0.08 1.41 -0.31 -0.12 -0.28 — — — — — — — — — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 11.5M 24.1M 50.9M 29.3M 27.6M 34.7M 39.4M
↳ YoY growth +108.6% +111.6% -42.4% -6.0% +25.9% +13.6%
↳ 5y CAGR +24.6% +10.4%
Borrowings, current (EUR) — — — — 13.1M 12.8M 3.35M 3.02M
Borrowings, non-current (EUR) — — — — 25.9M 27M 39.9M 35.6M
Lease liabilities (EUR) — 3.4M 3.62M 3.74M 3.62M 3.81M 9.33M 12.2M
Cash and deposits (EUR) 22.7M 17.6M 96.2M 113M 150M 60M 63.2M 17.8M
Intangible assets (EUR) — 6.07M 3.86M 3.23M 2.59M 1.94M 1M 3.55M
Right-of-use assets (EUR) — 3.35M 3.55M 3.64M 3.55M 3.73M 3.17M 2.76M
Net debt (borrowings + leases - cash) (EUR) — — — — -107M -16.4M -10.7M 32.9M
Cash flow detail
Operating cash flow (EUR) — -24.2M 279M 25.7M 38.3M -13.4M 6.03M 53.1M
Purchases of property, plant and equipment (EUR) — -3.96M -3M -7.8M -8.85M -16M -15M -6.46M
Change in receivables (cash effect) (EUR) — 16.5M 12.6M 26.8M -21.6M -1.78M 7.32M 4.99M
Change in inventories (cash effect) (EUR) — 2.42M 3.03M -1.4M 17.2M 11.5M 12.7M 2.13M
Change in payables (cash effect) (EUR) — -5.5M -4.65M -7.19M -1.79M -1.83M -11.2M 12.8M
Dividends paid (cash effect) (EUR) — 0.00 -8.82M -10.9M -11.8M -11.7M -11.4M -13.9M
Share buybacks (cash effect) (EUR) — -7.47M -63.7M -40.7M -50.2M -37.9M -18.6M -34.1M
Interest paid (cash effect) (EUR) — -2.32M -3.12M -3.37M -2.38M -2.42M -2.47M -887,000
Income taxes paid (cash effect) (EUR) — 0.00 -9.65M -7.86M 2.72M 16.6M 23.3M -3.71M
Share-based compensation (EUR) — 265,000 274,000 339,000 393,000 297,000 0.00 320,000
Operating cash flow before change in receivables (EUR) — -40.7M 266M -1.08M 59.9M -11.7M -1.29M 48.1M
Free cash flow (OCF - PPE - intangibles) (EUR) — -28.2M 276M 17.9M 29.5M -29.4M -8.99M 46.7M
Income detail
Research and development expense (EUR) — 50.6M 53.8M 72.2M 83.4M 99.3M 104M 95.2M
↳ 5y CAGR +15.4% +12.1%
Total comprehensive income (EUR) — -11.4M 137M 92.8M 49.3M 1.17M 26.1M 75M
Comprehensive income to owners (EUR) — -11.3M 137M 92.8M 49.3M 1.17M 26.1M 75M
Reported Feb 26, 2021 Feb 26, 2021 Feb 26, 2021 Feb 28, 2022 Feb 28, 2024 Feb 28, 2024 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

PHARMA MAR, S.A. (ticker PHM), listed in Spain.

ETFs Holding PHARMA MAR, S.A.

ETF Weight in ETF Shares Market value As of
DFIS 0.03% 23,762 $ 1.797M Nov 12, 2026
DFIC 0.00% 8,686 $ 657.004K Nov 12, 2026
DFSI 0.00% 476 $ 36.004K Nov 12, 2026
DFAI 0.00% 6,797 $ 514.121K Nov 12, 2026
DFAX 0.00% 831 $ 62.856K Nov 12, 2026